NEW YORK (GenomeWeb News) — GE Healthcare has agreed to license certain of its patents for biomagnetic nucleic-acid isolation to screening and diagnostics company NorDiag, GE Healthcare said yesterday.
GE Healthcare said the IP differs from conventional nucleic acid-isolation techniques due to the fact that the increased yield of nucleic acids it can isolate from disease-causing pathogens allows “diagnosis from smaller-volume patient samples.”
NorDiag CEO Mårten Wigstøl said the license will enable the company “widen [its] portfolio of products for clinical diagnostics,” and show shareholders that the company can “bring in technologies from large players such as GE Healthcare.”